礼来Eli Lilly & Co. (LLY) 2016年年度报告「NYSE」.pdf

1、ELI LILLY AND COMPANY2016 FINANCIAL REPORTNOTICE OF 2017 ANNUAL MEETINGPROXY STATEMENT201212.5%14.1%7.5%6.8%6.8%27.8%29.5%18.5%16.1%13.7%2013201420152016Return on Assets(ROA)Return on Shareholders Equity(ROE)ELI LILLY AND COMPANY AND SUBSIDIARIES(Dollars in millions,except per-share data)20162015Cha

2、nge%REVENUE$21,222.1$19,958.76RESEARCH AND DEVELOPMENT5,243.94,796.49RESEARCH AND DEVELOPMENT AS A PERCENT OF REVENUE24.7%24.0%NET INCOME$2,737.6$2,408.414EARNINGS PER SHAREDILUTED2.582.2614RECONCILING ITEMS1:Venezuela devaluation charge0.19 Novartis Animal Health inventory step-up0.10 Amortization

3、of intangible assets0.440.39 Acquired in-process research and development0.020.33 Asset impairment,restructuring,and other special charges0.290.25 Net charge related to repurchase of debt 0.09NON-GAAP EARNINGS PER SHAREDILUTED23.523.433DIVIDENDS PAID PER SHARE2.042.00CAPITAL EXPENDITURES1,037.01,066

4、.2(3)EMPLOYEES41,97541,27521.For more information on these reconciling items,see the Financial Results section of the Executive Overview on page F23 of the Financial Report.2.Numbers may not add due to rounding.Revenue Growth Across Therapeutic Areas($MILLIONS,PERCENT GROWTH)Return on Assets andShar

5、eholders EquityTotal ShareholderReturnROE increased in 2016 as a result of an increase of net income mainly due to higher sales for Trulicity and other new pharmaceutical products and lower acquired in-process research and development charges.Revenue in Endocrinology increased 15 percent primarily d

6、riven by growth of Trulicity,Forteo,Jardiance,Trajenta,and Basaglar.Oncology grew 6 percent primarily due to higher volumes for Cyramza and Erbitux,partially offset by lower volumes for Alimta,and Cardiovascular grew 5 percent mostly due to higher realized price for Cialis.Revenue in Neuroscience de